FDA’s Center for Veterinary Medicine (CVM) recently rolled out Phases 3 and 4 of its antimicrobial stewardship action plans covering fiscal years 2024-2028, but the impact on poultry is expected to be minimal due to the industry’s ongoing stewardship efforts.